LIR Life Sciences Initiates Animal Study on Transdermal Obesity Therapies

LIR Life Sciences Corp. has announced a controlled animal study to evaluate transdermal delivery of GLP/GIP-based obesity therapies using cell-penetrating peptides (CPP). This study marks a significant step in moving the company's transdermal platform from planning to functional testing in small animals.

The study aims to determine if a CPP-enabled, skin-applied therapy can achieve effective biological activity compared to subcutaneous injection. Blood glucose levels will be measured following a glucose challenge to assess glucose control efficacy of each method.

Using a standard glucose tolerance test, the study focuses on the broader applicability of CPP-enabled transdermal therapy for GLP/GIP-based incretin treatments, which could simplify administration and improve patient adherence.